Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said the registration application for the Polyethylene Glycol Electrolytes Powder was accepted by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.
The application was submitted by Shanghai Zhaohui Pharmaceutical, a unit of the pharmaceutical firm.
The drug is intended for bowel cleansing prior to procedures such as colonoscopy, barium enema X-ray imaging, and colorectal surgery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.